Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
plerixafor
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
Plerixafor is a small molecule hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) from the bone marrow into the peripheral blood for collection and subsequent autologous transplantation. It is primarily indicated for patients with non-Hodgkin's lymphoma or multiple myeloma who are undergoing autologous stem cell transplant. Plerixafor acts as an antagonist of the C-X-C chemokine receptor type 4 (CXCR4), blocking its interaction with stromal cell-derived factor-1α (SDF-1α), which disrupts the retention of HSCs in the bone marrow, thereby increasing their release into circulation[1][2][3][4].
- Brand names
- Mozobil
- Other names
- Mozobil
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)CXCR7 (CXC chemokine receptor 7)
Beyond the preview
Go deeper on plerixafor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on plerixafor.